Anetumab ravtansine (AR), an ADC composed of a fully human IgG1 anti-mesothelin mAb linked to the tubulin inhibitor DM4 via a cleavable linker, has demonstrated high cytotoxic activity in preclinical studies against mesothelin-expressing tumors such as mesothelioma, pancreatic cancer, NSCLC, and ovarian cancer [59]. This evidence concerns the gene MSLN and ovarian carcinoma.